+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Erythropoietin Treatment on Thyroid Dysfunction in Hemodialysis Patients with Renal Anemia

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The thyroid function was evaluated before and after 6 months of recombinant human erythropoietin (rhEPO) treatment (1,500-9,000 U/week) in 22 hemodialysis patients with hematocrit levels < 25%. Based upon the changes in hematocrit following rhEPO treatment, the patients were divided into two groups: 11 patients with an increase of the hematocrit level > 5% (group I) and 11 patients with an increase < 5% (group II). Before rhEPO administration, the levels of thyroid hormones, especially free thyroxine (T<sub>4</sub>) and free triiodothyronine (T<sub>3</sub>), were below the normal range despite normal thyrotropin values in most of the patients (low T<sub>4</sub>:7 cases in group I and 9 in group II; low T<sub>3</sub>:10 cases in group I and 10 in group II). RhEPO treatment significantly increased both total amount and free fractions of thyroid hormones in group I, whereas it did not affect these values in group II. Consequently, the pretreatment low T<sub>4</sub> or low T<sub>3</sub> status was resolved in a substantial number of the patients in group I (low T<sub>4</sub>:5 cases, low T<sub>3</sub>:4 cases). In addition, there was a significant correlation between the increases in hematocrit and free T<sub>3</sub> in all studied subjects (r = 0.603; p < 0.05). These results suggest that anemia may participate to some extent in the pathogenesis of thyroid dysfunction in hemodialysis patients with renal anemia.

          Related collections

          Author and article information

          S. Karger AG
          16 December 2008
          : 66
          : 3
          : 307-311
          2nd Department of Internal Medicine, Toyma Medical and Pharmaceutical University, Toyama, Japan
          187828 Nephron 1994;66:307–311
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper

          Cardiovascular Medicine, Nephrology

          Thyroid function, Hemodialysis, Erythropoietin


          Comment on this article